Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of GHZ339 in moderate to severe atopic dermatitis
jRCT2031250233Phase 2Suspended
- Sponsor
- Novartis
- Start
- Jul 2025
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of GHZ339 in atopic dermatitis (AD) (5 arms), sponsored by Novartis. Primary endpoint: Change from baseline in Eczema Area and Severity Index (EASI) score at Week 16. Started Jul 2025; status: suspended.
02
Drugs
GHZ339
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031250233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250233.